Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Orgenesis Inc - SIC # 5047 - MEDICAL, DENTAL, AND HOSPITAL EQUIPMENT AND SUPPLIES
Ticker
Exchange
SIC #
Website
Latest Ticker
ORGS
Nasdaq
5047
https://www.orgenesis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Orgenesis Inc
Orgenesis Provides Year End Business Update
- Apr 15th, 2024 9:07 pm
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
- Apr 10th, 2024 4:00 pm
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
- Mar 18th, 2024 12:30 pm
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
- Mar 13th, 2024 12:30 pm
Orgenesis Inc. Announces $2.3 Million Private Placement
- Mar 4th, 2024 1:30 pm
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
- Feb 29th, 2024 1:30 pm
EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
- Jan 31st, 2024 3:45 pm
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
- Jan 31st, 2024 2:15 pm
Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon
- Nov 22nd, 2023 11:04 am
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
- Nov 14th, 2023 1:30 pm
Orgenesis Provides Business Update for the Third Quarter of 2023
- Nov 13th, 2023 9:15 pm
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
- Nov 8th, 2023 2:00 pm
Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
- Nov 2nd, 2023 12:00 pm
Orgenesis Announces Withdrawal of Proposed Public Offering
- Oct 31st, 2023 1:30 am
Orgenesis Announces Proposed Underwritten Public Offering
- Oct 30th, 2023 8:07 pm
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States
- Sep 21st, 2023 12:00 pm
Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support
- Sep 6th, 2023 11:00 am
Is Orgenesis (ORGS) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
- Aug 28th, 2023 4:36 pm
Orgenesis Inc (ORGS): A Deep Dive into Its Performance Potential
- Aug 28th, 2023 4:15 pm
Orgenesis (ORGS): A Value Trap in Disguise?
- Aug 23rd, 2023 11:36 pm
Scroll